Browsing by Subject "comorbidity assessment"

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    MACVIA-ARIA Sentinel NetworK for allergic rhinitis (MASK-rhinitis): The new generation guideline implementation
    (Blackwell Publishing Ltd, 2015) Bousquet J.; Schunemann H.J.; Fonseca J.; Samolinski B.; Bachert C.; Canonica G.W.; Casale T.; Cruz A.A.; Demoly P.; Hellings P.; Valiulis A.; Wickman M.; Zuberbier T.; Bosnic-Anticevitch S.; Bedbrook A.; Bergmann K.C.; Caimmi D.; Dahl R.; Fokkens W.J.; Grisle I.; Lodrup Carlsen K.; Mullol J.; Muraro A.; Palkonen S.; Papadopoulos N.; Passalacqua G.; Ryan D.; Valovirta E.; Yorgancioglu A.; Aberer W.; Agache I.; Adachi M.; Akdis C.A.; Akdis M.; Annesi-Maesano I.; Ansotegui I.J.; Anto J.M.; Arnavielhe S.; Arshad H.; Baiardini I.; Baigenzhin A.K.; Barbara C.; Bateman E.D.; Beghé B.; Bel E.H.; Ben Kheder A.; Bennoor K.S.; Benson M.; Bewick M.; Bieber T.; Bindslev-Jensen C.; Bjermer L.; Blain H.; Boner A.L.; Boulet L.P.; Bonini M.; Bonini S.; Bosse I.; Bourret R.; Bousquet P.J.; Braido F.; Briggs A.H.; Brightling C.E.; Brozek J.; Buhl R.; Burney P.G.; Bush A.; Caballero-Fonseca F.; Calderon M.A.; Camargos P.A.M.; Camuzat T.; Carlsen K.H.; Carr W.; Cepeda Sarabia A.M.; Chavannes N.H.; Chatzi L.; Chen Y.Z.; Chiron R.; Chkhartishvili E.; Chuchalin A.G.; Ciprandi G.; Cirule I.; Correia De Sousa J.; Cox L.; Crooks G.; Costa D.J.; Custovic A.; Dahlen S.E.; Darsow U.; De Carlo G.; De Blay F.; Dedeu T.; Deleanu D.; Denburg J.A.; Devillier P.; Didier A.; Dinh-Xuan A.T.; Dokic D.; Douagui H.; Dray G.; Dubakiene R.; Durham S.R.; Dykewicz M.S.; El-Gamal Y.; Emuzyte R.; Fink Wagner A.; Fletcher M.; Fiocchi A.; Forastiere F.; Gamkrelidze A.; Gemicioʇlu B.; Gereda J.E.; González Diaz S.; Gotua M.; Grouse L.; Guzmán M.A.; Haahtela T.; Hellquist-Dahl B.; Heinrich J.; Horak F.; Hourihane J.O.B.; Howarth P.; Humbert M.; Hyland M.E.; Ivancevich J.C.; Jares E.J.; Johnston S.L.; Joos G.; Jonquet O.; Jung K.S.; Just J.; Kaidashev I.P.; Kalayci O.; Kalyoncu A.F.; Keil T.; Keith P.K.; Khaltaev N.; Klimek L.; Koffi N'Goran B.; Kolek V.; Koppelman G.H.; Kowalski M.L.; Kull I.; Kuna P.; Kvedariene V.; Lambrecht B.; Lau S.; Larenas-Linnemann D.; Laune D.; Le L.T.T.; Lieberman P.; Lipworth B.; Li J.; Louis R.; Magard Y.; Magnan A.; Mahboub B.; Majer I.; Makela M.J.; Manning P.; De Manuel Keenoy E.; Marshall G.D.; Masjedi M.R.; Maurer M.; Mavale-Manuel S.; Melén E.; Melo-Gomes E.; Meltzer E.O.; Merk H.; Miculinic N.; Mihaltan F.; Milenkovic B.; Mohammad Y.; Molimard M.; Momas I.; Montilla-Santana A.; Morais-Almeida M.; Mösges R.; Namazova-Baranova L.; Naclerio R.; Neou A.; Neffen H.; Nekam K.; Niggemann B.; Nyembue T.D.; O'Hehir R.E.; Ohta K.; Okamoto Y.; Okubo K.; Ouedraogo S.; Paggiaro P.; Pali-Schöll I.; Palmer S.; Panzner P.; Papi A.; Park H.S.; Pavord I.; Pawankar R.; Pfaar O.; Picard R.; Pigearias B.; Pin I.; Plavec D.; Pohl W.; Popov T.A.; Portejoie F.; Postma D.; Potter P.; Price D.; Rabe K.F.; Raciborski F.; Radier Pontal F.; Repka-Ramirez S.; Robalo-Cordeiro C.; Rolland C.; Rosado-Pinto J.; Reitamo S.; Rodenas F.; Roman Rodriguez M.; Romano A.; Rosario N.; Rosenwasser L.; Rottem M.; Sanchez-Borges M.; Scadding G.K.; Serrano E.; Schmid-Grendelmeier P.; Sheikh A.; Simons F.E.R.; Sisul J.C.; Skrindo I.; Smit H.A.; Solé D.; Sooronbaev T.; Spranger O.; Stelmach R.; Strandberg T.; Sunyer J.; Thijs C.; Todo-Bom A.; Triggiani M.; Valenta R.; Valero A.L.; Van Hage M.; Vandenplas O.; Vezzani G.; Vichyanond P.; Viegi G.; Wagenmann M.; Walker S.; Wang D.Y.; Wahn U.; Williams D.M.; Wright J.; Yawn B.P.; Yiallouros P.K.; Yusuf O.M.; Zar H.J.; Zernotti M.E.; Zhang L.; Zhong N.; Zidarn M.; Mercier J.
    Several unmet needs have been identified in allergic rhinitis: identification of the time of onset of the pollen season, optimal control of rhinitis and comorbidities, patient stratification, multidisciplinary team for integrated care pathways, innovation in clinical trials and, above all, patient empowerment. MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) is a simple system centred around the patient which was devised to fill many of these gaps using Information and Communications Technology (ICT) tools and a clinical decision support system (CDSS) based on the most widely used guideline in allergic rhinitis and its asthma comorbidity (ARIA 2015 revision). It is one of the implementation systems of Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA). Three tools are used for the electronic monitoring of allergic diseases: a cell phone-based daily visual analogue scale (VAS) assessment of disease control, CARAT (Control of Allergic Rhinitis and Asthma Test) and e-Allergy screening (premedical system of early diagnosis of allergy and asthma based on online tools). These tools are combined with a clinical decision support system (CDSS) and are available in many languages. An e-CRF and an e-learning tool complete MASK. MASK is flexible and other tools can be added. It appears to be an advanced, global and integrated ICT answer for many unmet needs in allergic diseases which will improve policies and standards. © 2015 John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
  • No Thumbnail Available
    Item
    Comparison of hydroxychloroquine plus moxifloxacin versus hydroxychloroquine alone on corrected QT interval prolongation in COVID-19 patients
    (Czech Society of Cardiology Z.S, 2021) Yavuz V.; Ozyurtlu F.; Cetin N.
    Background: Hydroxychloroquine (HCQ) alone or with some antibiotic and antiviral agents is used off label in the treatment of Coronavirus Disease 2019 (COVID-19). It seems that the most important safety problem about these medications are their cardiac side effects. Although there are data on arrhythmogenic events associated with the use of HCQ alone, such as corrected QT (QTc) prolongation, Torsade de pointes (TdP) or bradycardia, there are insufficient data on its combination with moxifloxacin (MOX). Objective: The aim of our study is to analyze the effect of HCQ alone or in combination with the use of MOX on QTc interval, heart rate, and arrhythmic events in patients with a diagnosis of COVID-19. Methods: This is a single center cohort study of non-intensive care unit (ICU) patients hospitalized with clinical signs consistent with pneumonia and at least one positive COVID-19 nasopharyngeal polymerase chain reaction test result. QTc intervals and heart rates in patients whose treatment consisted of HCQ alone or its separate combination with MOX at baseline and post-treatment were calculated and compared. Results: 312 patients were included (median age of 42 [IQR: 31.25–57.75] years, 54.16% male). Patients were divided into two groups based on their in-hospital treatment strategy as follows: HCQ alone (n: 166, 53.20%) or HCQ + MOX (n: 146, 46.79%). As compared to baseline, QTc intervals were significantly increased in all patients after treatment (406.00 [388.00–422.00] ms vs 418.00 [401.00–435.00] ms, p< 0.001). When the baseline QTc intervals were evaluated, there was no statistically significant difference between HCQ alone and HCQ + MOX groups (403.00 [384.50–419.00] ms vs. 409.50 [390.00–425.00] ms, p: 0.086). After treatment period, QTc intervals were significantly higher in HCQ + MOX group compared to the group in which patients only used HCQ (413.00 [398.00–430.00] ms vs. 426.50 [405.00–441.00] ms, p< 0.001). We found a significant decrease in heart rate in both groups after treatment period. From 79.00 (70.00–88.00) bpm to 70.00 (63.00–79.00) bpm in HCQ alone group (p< 0.001) and from 80.00 (70.00–88.00) bpm to 70.50 (63.00–78.75) bpm in HCQ + MOX group (p< 0.001). On the other hand, no statistically significant difference was observed between the groups in terms of heart rates either before or after the treatment. Conclusion: In this cohort study, patients who received HCQ for the treatment of COVID-19 were at high risk of QTc prolongation, and concurrent treatment with MOX was associated with greater changes in QTc. However, none of patients experienced malignant ventricular arrhythmia or death during treatment. Clinicians should carefully weigh risks and benefits with close monitoring of QTc if considering treatment with HCQ especially concomitant use with MOX. Further prospective studies are needed to determine the exact implications of these drugs on arrhythmias in patients with COVID-19. © 2021, ČKS.
  • No Thumbnail Available
    Item
    The success of the Cystic Fibrosis Registry of Turkey for improvement of patient care
    (John Wiley and Sons Inc, 2022) Asfuroglu P.; Sismanlar Eyuboglu T.; Aslan A.T.; Gursoy T.R.; Emiralioglu N.; Yalcin E.; Kiper N.; Sen V.; Sen H.S.; Altintas D.U.; Ozcan D.; Kilinc A.A.; Cokugras H.; Baskan A.K.; Yazan H.; Erenberk U.; Dogan G.; Unal G.; Yilmaz A.I.; Keskin O.; Arik E.; Kucukosmanoglu E.; Irmak I.; Damadoglu E.; Ozturk G.K.; Gulen F.; Basaran A.E.; Bingol A.; Cekic S.; Sapan N.; Kilic G.; Harmanci K.; Kose M.; Ozdemir A.; Tugcu G.D.; Polat S.E.; Hangul M.; Ozcan G.; Aydin Z.G.G.; Yuksel H.; Topal E.; Ozdogan S.; Caltepe G.; Suleyman A.; Can D.; Ekren P.K.; Bal C.M.; Kilic M.; Cinel G.; Cobanoglu N.; Pekcan S.; Cakir E.; Ozcelik U.; Dogru D.
    Background: Cystic fibrosis (CF) registries play an essential role in improving disease outcomes of people with CF. This study aimed to evaluate the association of newly established CF registry system in Turkey on follow-up, clinical, growth, treatment, and complications of people with this disease. Methods: Age at diagnosis, current age, sex, z-scores of weight, height and body mass index (BMI), neonatal screening results, pulmonary function tests, history of meconium ileus, medications, presence of microorganisms, and follow-up were evaluated and compared to data of people with CF represented in both 2017 and 2019 registry data. Results: There were 1170 people with CF in 2017 and 1637 in 2019 CF registry. Eight hundred and fourteen people were registered in both 2017 and 2019 of whom z-scores of heights and BMI were significantly higher in 2019 (p = 0.002, p =0.039, respectively). Inhaled hypertonic saline, bronchodilator, and azithromycin usages were significantly higher in 2019 (p =0.001, p = 0.001, p = 0.003, respectively). The percent predicted of forced expiratory volume in 1 sec and forced vital capacity were similar in 2017 and 2019 (88% and 89.5%, p = 0.248 and 84.5% and 87%, p =0.332, respectively). Liver diseases and osteoporosis were significantly higher, and pseudo-Bartter syndrome (PBS) was significantly lower in 2019 (p = 0.011, p = 0.001, p = 0.001, respectively). Conclusions: The z-scores of height and BMI were higher, the use of medications that protect and improve lung functions was higher and incidence of PBS was lower in 2019. It was predicted that registry system increased the care of people with CF regarding their follow-up. The widespread use of national CF registry system across the country may be beneficial for the follow-up of people with CF. © 2022 Wiley Periodicals LLC.